10X Genomics Inc

10X Genomics: Morgan Stanley’s equal‑weight downgrade reveals neutral outlook, limited upside, and caution amid negative P/E and market volatility.

10X Genomics Inc. is at a crossroads, with Wall Street analysts offering conflicting views on its future, as some predict a potential 55.85% rally while others warn of deeper systemic issues.